Government psoriasis research funding down over last decade while NIH budget up 148%

May 17, 2004

Portland, Ore., May 17, 2004 - Armed with statistics showing psoriasis research funding languished as the National Institutes of Health (NIH) enjoyed record budget increases, the National Psoriasis Foundation released its 2004 legislative agenda today as its members gathered in Washington, DC to meet with Congressional offices. The top policy goal of the Psoriasis Foundation will be to secure additional funding for psoriasis research. Over the last decade, as NIH funding increased by 148%, psoriasis research funding at NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) actually decreased by 13%.

"The five million Americans with psoriasis have missed out on the historic growth at the National Institutes of Health," said Gail M. Zimmerman, president and CEO of the Psoriasis Foundation. "While the reasons for this are complex, the federal government is apparently spending less than $1 per patient on psoriasis research annually. Given the human costs of psoriasis as well as the more than $2 billion spent annually treating this disease, we are asking Congress to increase the federal commitment to psoriasis research."

Psoriasis Foundation members from around the country are in Washington, DC today meeting with dozens of Congressional offices, unveiling the legislative agenda and educating lawmakers about the disease. In addition to urging increased research on psoriasis, the legislative agenda calls for Congressional support for NIH's Autoimmune Diseases Research Plan; for a government effort to increase the number of physicians and scientists treating and studying psoriasis; and for improved patient access to treatments and fair reimbursement rates for these treatments.

"I look forward to meeting with Congressional offices to explain the devastating impact psoriasis can have on people, and the importance of increasing research funding for this disease," said Isabel Esteviz, a Psoriasis Foundation member from Chicago, Ill. who is in Washington for the meetings. "We psoriasis patients need our fair share of the great work being done at NIH."

NIAMS funding for psoriasis research was $4.7 million in fiscal year 1995, and is just $4.1 million in FY 2004, a reduction of 13% before inflation. During the same time, the NIH budget grew from $11.3 billion to $28 billion, an increase of 148%. (NIH also funds some psoriasis research through other Institutes at NIH, but those lesser figures are not yet available.)

"NIAMS supports important research on behalf of psoriasis patients," Ms. Zimmerman added. "We look forward to working with Congress to ensure that NIAMS has the resources it needs to enhance its ability to conduct cutting-edge psoriasis research in the future."
-end-
About Psoriasis
Psoriasis is a lifelong skin disease that occurs when faulty signals in the immune system cause skin cells to regenerate too quickly--every three to four days instead of the usual 30-day cycle. Extra skin cells build up on the skin's surface, forming red, flaky, scaly lesions that can itch, crack, bleed and be extremely painful. Psoriasis generally appears on the joints, limbs and scalp but it can appear anywhere on the body, covering some people from head to toe. More than 5 million Americans have psoriasis and/or psoriatic arthritis, a degenerative disease of the joints and connective tissues associated with psoriasis. Psoriasis typically first strikes people between the ages of 15 and 35, but can affect anyone at any age, including children.

About the National Psoriasis Foundation
The National Psoriasis Foundation is the leading nonprofit organization fighting to improve the quality of life of the more than 5 million Americans diagnosed with psoriasis and/or psoriatic arthritis and their families. Its mission is to educate people about these diseases and their treatments, raise public awareness, and support ongoing research. The organization is headquartered in Portland, Ore. For more information, please call the Psoriasis Foundation at 800.723.9166 or visit http://www.psoriasis.org.

National Psoriasis Foundation

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.